Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VentriGel in Post-MI Left Ventricular Remodeling
NCT02305602Phase 1Completed
- Sponsor
- Ventrix, Inc.
- Start
- Sep 2015
- Primary completion
- Sep 2018
- Modality
- Hydrogel Systems, Device-based Delivery
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of VentriGel in myocardial infarction (MI), heart failure (HF) and Left ventricular remodeling (LVR), sponsored by Ventrix, Inc. Primary endpoint: Incidence of serious adverse events at 6 months. Started Sep 2015; status: completed.
02
Drugs
VentriGel
03
Conditions
myocardial infarction (MI)heart failure (HF)Left ventricular remodeling (LVR)
Beyond the preview
Go deeper on NCT02305602.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02305602.